Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | active not recruiting | Phase 2 | 6,452 | National Cancer Institute (NCI)NIH | 3 | Sep 29, 2026 | clinicaltrials |
| NCT04708418 | A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma | active not recruiting | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 |
| Sep 29, 2026 |
| clinicaltrials |
| NCT04044859 | ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | active not recruiting | Phase 1 | 120 | USWM CT, LLCINDUSTRY | 3 | Sep 23, 2026 | clinicaltrials |
| NCT05913388 | GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 2 | 12 | Providence Health & ServicesOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04464759 | A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma(LIMIT) | active not recruiting | Phase 1 / Phase 2 | 41 | Ravi Amaravadi, MDOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05279027 | Zr89 + PET Companion Trial | active not recruiting | Early Phase 1 | 6 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04990726 | Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors | active not recruiting | — | 126 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05863052 | Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population | active not recruiting | — | 72 | University of OklahomaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06906822 | PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients(PlugIN) | active not recruiting | Phase 2 | 60 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03605771 | Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain(GEM-1801) | active not recruiting | — | 400 | Grupo Español Multidisciplinar de MelanomaOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04940299 | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma | active not recruiting | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT01303341 | Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma | active not recruiting | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT02196181 | Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread | active not recruiting | Phase 2 | 280 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04462406 | Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial | active not recruiting | Phase 2 | 150 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05358938 | Exercise to Boost Response to Checkpoint Blockade Immunotherapy | active not recruiting | Early Phase 1 | 22 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05524935 | Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma | active not recruiting | Phase 2 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT00937937 | Dinaciclib in Treating Patients With Stage IV Melanoma | active not recruiting | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01134614 | Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | active not recruiting | Phase 2 | 245 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03149029 | Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma | active not recruiting | Phase 2 | 16 | Massachusetts General HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001) | active not recruiting | Phase 1 / Phase 2 | 733 | OncoC4, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT06101134 | A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations | active not recruiting | Phase 2 | 100 | Bristol-Myers SquibbINDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT06500455 | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | active not recruiting | Phase 3 | 274 | NRG OncologyOTHER | 4 | Sep 14, 2026 | clinicaltrials |
| NCT04140500 | Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 170 | Hoffmann-La RocheINDUSTRY | 9 | Sep 11, 2026 | clinicaltrials |
| NCT05470283 | Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma | active not recruiting | Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05640193 | A Study of LN-144 in People With Metastatic Melanoma to the Brain | active not recruiting | Phase 1 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT01364051 | Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies | active not recruiting | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05557045 | A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 | active not recruiting | Phase 1 | 98 | Jazz PharmaceuticalsINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT01480154 | Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer | active not recruiting | Phase 1 | 62 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT01274338 | Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery | active not recruiting | Phase 3 | 1,673 | National Cancer Institute (NCI)NIH | 2 | Sep 8, 2026 | clinicaltrials |
| NCT03122522 | A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy | active not recruiting | Phase 2 | 70 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT03897881 | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | active not recruiting | Phase 2 | 267 | ModernaTX, Inc.INDUSTRY | 2 | Sep 8, 2026 | clinicaltrials |
| NCT01366144 | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | active not recruiting | Phase 1 | 94 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04013854 | Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab | active not recruiting | Phase 2 | 67 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04657991 | A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma | active not recruiting | Phase 3 | 257 | PfizerINDUSTRY | 27 | Sep 3, 2026 | clinicaltrials |
| NCT04562129 | IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients | active not recruiting | Phase 2 | 18 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05089370 | Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma | active not recruiting | Phase 1 / Phase 2 | 8 | University of Colorado, DenverOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04557956 | Testing the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment | active not recruiting | Phase 1 / Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04866680 | Personalized Circulating DNA Follow-up in Melanoma (PERCIMEL)(PERCIMEL) | active not recruiting | N/A | 136 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05355701 | A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | active not recruiting | Phase 1 | 103 | PfizerINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT05538130 | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | active not recruiting | Phase 1 | 148 | PfizerINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT06305247 | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 36 | IpsenINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT07796594 | Integration of Whole-Genome Sequencing PrOfiles and ImmuNe StATus in Cancer(SONATA) | active not recruiting | N/A | 180 | Amsterdam UMC, location VUmcOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT02224781 | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma | active not recruiting | Phase 3 | 267 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02339571 | A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma | active not recruiting | Phase 2 / Phase 3 | 600 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02506153 | Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery | active not recruiting | Phase 3 | 1,301 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2026 | clinicaltrials |
| NCT05053230 | A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer(IMPROVE) | active not recruiting | N/A | 324 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05625399 | A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma(RELATIVITY-127) | active not recruiting | Phase 3 | 579 | Bristol-Myers SquibbINDUSTRY | 19 | Aug 26, 2026 | clinicaltrials |
| NCT06598137 | Study to Examine Lesions of the Skin Using Confocal Laser Microscopy | active not recruiting | — | 645 | LMU KlinikumOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT02858921 | Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma(Neo Trio) | active not recruiting | Phase 2 | 60 | Melanoma Institute AustraliaOTHER | 1 | Aug 24, 2026 | clinicaltrials |
Data updated 18 hours agoSource updated Sep 29, 2026source: clinicaltrials